<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03907800</url>
  </required_header>
  <id_info>
    <org_study_id>RJBC1801</org_study_id>
    <nct_id>NCT03907800</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer</brief_title>
  <acronym>NeoPATH</acronym>
  <official_title>Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of nab-paclitaxel combined with carboplatin for Chinese
      patients with triple-negative and HER2-positive breast cancer in the neoadjuvant setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response (ypT0/is ypN0) rate</measure>
    <time_frame>16 weeks (at the time of definitive surgery)</time_frame>
    <description>Absence of invasive cancer in the breast and axillary nodes, irrespective of ductal carcinoma in situ.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Invasive disease-free survival (IDFS)</measure>
    <time_frame>5 years</time_frame>
    <description>IDFS is defined as the time period between registration and first event (ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, death attributable to any cause, contralateral invasive breast cancer, second primary nonbreast invasive cancer)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant disease-free survival (DDFS)</measure>
    <time_frame>5 years</time_frame>
    <description>DDFS is defined as the time period between registration and first event (distant recurrence, death attributable to any cause, second primary nonbreast invasive cancer)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>16 weeks (at the time of definitive surgery)</time_frame>
    <description>ORR includes all patients whose cancer has a partial or complete response according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast conservation rate</measure>
    <time_frame>16 weeks (at the time of definitive surgery)</time_frame>
    <description>To determine the breast conservation rate after neoadjuvant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability and safety: number of patients whose treatment had to be reduced, delayed or permanently stopped</measure>
    <time_frame>during treatment (16 weeks)</time_frame>
    <description>Descriptive statistics will be given on the number of patients whose treatment had to be reduced, delayed or permanently stopped.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>HER2-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Nab-paclitaxel + Carboplatin ± Herceptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>125 mg/m² weekly, infusion, 3 weeks on 1 week off, applicated for four cycles.</description>
    <arm_group_label>Nab-paclitaxel + Carboplatin ± Herceptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC 2, weekly, 3 weeks on 1 week off, applicated for 4 cycles</description>
    <arm_group_label>Nab-paclitaxel + Carboplatin ± Herceptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin</intervention_name>
    <description>In case of HER2-positive, patients receive Herceptin weekly during all cycles.</description>
    <arm_group_label>Nab-paclitaxel + Carboplatin ± Herceptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent for all study according to local regulatory requirements
             prior to beginning specific protocol procedures.

          2. Age at diagnosis ≥ 18 years, female.

          3. Histologically confirmed diagnosis of HER2-opsitive or triple-negative breast cancer.
             ER/PR-negativity is defined as ≤1% stained cells； HER2-positivity is defined as IHC 3+
             or in-situ hybridisation (ISH) ratio &gt;2.0.

          4. cT2-4NanyM0 or cTanyN1-3M0

          5. ECOG ≤ 1, LVEF ≥ 55%.

          6. Laboratory requirements: for hematology, absolute neutrophil count (ANC) ≥ 1.5 × 109 /
             L and platelets ≥ 100 × 109 / L and hemoglobin ≥ 90 g/L; for hepatic function, total
             bilirubin ≤ 1.5 × UNL, AST and ALT ≤ 2.5 × UNL; for renal function, SCr ≤ 1.5 × UNL

          7. Patients must be available and compliant for treatment and follow-up.

        Exclusion Criteria:

          1. Prior chemotherapy, endocrine therapy or radiation therapy for any malignancy.

          2. Known or suspected congestive heart failure (&gt; NYHA I)

          3. Currently active infection or severe symptomatic visceral disease.

          4. Definite contraindications for the use of corticosteroids or known hypersensitivity
             reaction to one of the compounds or incorporated substances used in this protocol

          5. rior malignancy with a disease-free survival of &lt; 5 years, except curatively treated
             basalioma of the skin, pTis of the cervix uteri.

          6. Participation in another clinical trial with any investigational, not marketed drug
             within 30 days prior to study entry.

          7. Pregnant or lactating patients. Patients of childbearing potential must implement
             adequate non-hormonal contraceptive measures (barrier methods, intrauterine
             contraceptive devices, sterilization) during study treatment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zhu, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiayi Wu, Dr.</last_name>
    <phone>0086-21-64370045</phone>
    <phone_ext>602268</phone_ext>
    <email>pinkscorpio@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhu, Prof.</last_name>
      <phone>0086-21-64370045</phone>
      <phone_ext>602178</phone_ext>
      <email>pinkscorpio@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jiayi Wu, Dr.</last_name>
      <phone>0086-21-64370045</phone>
      <phone_ext>602268</phone_ext>
      <email>zhuli8@yeah.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 5, 2019</study_first_submitted>
  <study_first_submitted_qc>April 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2019</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Li Zhu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

